Cancer gene therapy: Part 2. Candidate transgenes and their clinical development.
Harrington
Kevin J
KJ
CRC Centre for Cell and Molecular Biology, Institute for Cancer Research, London, UK. kevinh@icr.ac.uk
Melcher
Alan A
AA
Bateman
Andrew R
AR
Ahmed
Atique
A
Vile
Richard G
RG
D019496:Cancer Vaccines / Q000235:genetics / Q000627:therapeutic use; D016207:Cytokines / Q000235:genetics; D004798:Enzymes / Q000235:genetics; D016147:Genes, Tumor Suppressor; D015316:Genetic Therapy; D006801:Humans; D008285:Major Histocompatibility Complex / Q000235:genetics; D009369:Neoplasms / Q000628:therapy*; D016376:Oligonucleotides, Antisense / Q000235:genetics / Q000627:therapeutic use; D011355:Prodrugs / Q000627:therapeutic use; D019076:Transgenes
D019496:Cancer Vaccines; D016207:Cytokines; D004798:Enzymes; D016376:Oligonucleotides, Antisense; D011355:Prodrugs